US20110172753A1 - Endoprostheses - Google Patents

Endoprostheses Download PDF

Info

Publication number
US20110172753A1
US20110172753A1 US13053461 US201113053461A US2011172753A1 US 20110172753 A1 US20110172753 A1 US 20110172753A1 US 13053461 US13053461 US 13053461 US 201113053461 A US201113053461 A US 201113053461A US 2011172753 A1 US2011172753 A1 US 2011172753A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
polyol
polymeric
material
coating
endoprosthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13053461
Inventor
Ronald A. Sahatjian
Francisca Tan
Patrick T. Mather
Changdeng Liu
Qing Ge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut
Boston Scientific Scimed Inc
Original Assignee
University of Connecticut
Boston Scientific Scimed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02Inorganic materials
    • A61L31/022Metals or alloys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402Anaestetics, analgesics, e.g. lidocaine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/24Structurally defined web or sheet [e.g., overall dimension, etc.]
    • Y10T428/24802Discontinuous or differential coating, impregnation or bond [e.g., artwork, printing, retouched photograph, etc.]
    • Y10T428/24926Discontinuous or differential coating, impregnation or bond [e.g., artwork, printing, retouched photograph, etc.] including ceramic, glass, porcelain or quartz layer

Abstract

Endoprosthesis are disclosed.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • [0001]
    This application is a divisional application (and claims the benefit of priority under 35 USC 120) of U.S. application Ser. No. 11/111,509, filed on Apr. 21, 2005 which is a continuation-in-part of U.S. application Ser. No. 10/958,435, filed Oct. 5, 2004, now U.S. Pat. No. 7,794,494; which is a continuation-in-part of U.S. patent application Ser. No. 10/683,314, filed Oct. 10, 2003, now abandoned; which claims the benefit of priority from U.S. Provisional Patent Application Ser. No. 60/488,323, filed Jul. 18, 2003, and U.S. Provisional Patent Application Ser. No. 60/488,590, filed Jul. 18, 2003. The content of each application above is hereby incorporated by reference herein in their entirety.
  • TECHNICAL FIELD
  • [0002]
    This invention relates to endoprotheses.
  • BACKGROUND
  • [0003]
    The body includes various passageways such as arteries, other blood vessels, and other body lumens. These passageways sometimes become occluded or weakened. For example, the passageways can be occluded by a tumor, restricted by plaque, or weakened by an aneurysm. When this occurs, the passageway can be reopened or reinforced, or even replaced, with a medical endoprosthesis. An endoprosthesis is typically a tubular member that is placed in a lumen in the body. Examples of endoprosthesis include stents, covered stents, and stent-grafts.
  • [0004]
    Endoprosthesis can be delivered inside the body by a catheter that supports the endoprosthesis in a compacted or reduced-size form as the endoprosthesis is transported to a desired site. Upon reaching the site, the endoprosthesis is expanded, for example, so that it can contact the walls of the lumen.
  • [0005]
    The expansion mechanism may include forcing the endoprosthesis to expand radially. For example, the expansion mechanism can include the catheter carrying a balloon, which carries a balloon-expandable endoprosthesis. The balloon can be inflated to deform and to fix the expanded endoprosthesis at a predetermined position in contact with the lumen wall. The balloon can then be deflated, and the catheter withdrawn.
  • [0006]
    In another delivery technique, the endoprosthesis is formed of an elastic material that can be reversibly compacted and expanded, e.g., elastically or through a material phase transition. During introduction into the body, the endoprosthesis is restrained in a compacted condition. Upon reaching the desired implantation site, the restraint is removed, for example, by retracting a restraining device such as an outer sheath, enabling the endoprosthesis to self-expand by its own internal elastic restoring force.
  • [0007]
    Passageways containing endoprotheses can become re-occluded. Re-occlusion of such passageways is known as restenosis. It has been observed that certain drugs can inhibit the onset of restenosis when the drug is coated on the endoprosthesis.
  • SUMMARY
  • [0008]
    Generally, the invention relates to a coated endoprosthesis. The endoprosthesis may be, e.g., a metal or a metal alloy stent. The coating may include a therapeutic agent, e.g., a restenosis inhibiting agent, and may degrade in biological systems.
  • [0009]
    In one aspect, the invention features an implantable endoprosthesis including a tubular member having a coating. The coating includes a polymeric material that includes a reaction product of a polyol, an isocyanate and a silsesquioxane having at least two pendent hydroxyl groups.
  • [0010]
    In some embodiments, the coating includes a therapeutic agent. The coating includes, e.g., between about 1 percent by weight and about 35 by weight therapeutic agent or between about 5 percent by weight and about 25 by weight therapeutic agent. In a specific embodiment, the therapeutic agent inhibits restenosis. An example of such a therapeutic agent is paclitaxel.
  • [0011]
    The polymeric material can be configured to fully release its therapeutic agent in less than seven days in blood at body temperature and/or to degrade in less than 365 days in blood at body temperature.
  • [0012]
    Polyols include, e.g., polyethylene glycol, polycaprolactone, polycyclooctene, trans-1,4 butadiene, transisoprene, polynorbornene and polymethacrylate copolymer, polycaprolactone-polylactide copolymer, polycaprolactone-polyglycolide copolymer, polycaprolactone-polylactide-polyglycolide copolymer, polylactide, polycaprolactone-poly(β-hydroxybutyric acid) copolymer, poly(β-hydroxybutyric acid) or mixtures of these polyols.
  • [0013]
    In a specific embodiment, the polyol has only two pendent hydroxyl groups, and the hydroxyl groups are disposed at ends of the polyol.
  • [0014]
    The isocyanate can be, e.g., a diisocyanate, e.g., 4,4′ diphenyl methylene diisocyanate, toluene-2,4-diisocyanate, toluene-2,6-diisocyanate, hexamethylene-1,6-diisocyanate, 4,4′-diphenylmethane diisocyanate, isophorone diisocyanate, and hydrogenated 4,4′-diphenylmethane diisocyanate or mixtures of these.
  • [0015]
    The silsesquioxane can be, e.g., 1-(2-trans-cyclohexanediol)ethyl-3,5,7,9,11,13,15-isobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxane, 2-ethyl-2-[3-[[(heptaisobutylpentacyclo-[9.5.1.13,9.15,15. 17,13]octasiloxanyl)oxy]dimethylsilyl]-propoxy]propane-1,3-diol, 1-(2,3-propanediol)propoxy-3,5,7,9,11,13,15-isobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxane, 2-ethyl-2-[3-[[(heptaisobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxanyl)oxy]dimethylsilyl]-propoxy]methyl]-1,3-propanediol or mixtures of these.
  • [0016]
    In some embodiments, a weight ratio of the polyol to the silsesquioxane is from about 1:2 to about 1:30, or from about 1:5 to about 1:25.
  • [0017]
    The coating can have a thickness, e.g., of between about 3 micron and about 150 micron before the implantable endoprosthesis is expanded or between about 20 micron and 50 micron before the implantable endoprosthesis is expanded.
  • [0018]
    A coverage of the polymeric material on the tubular member can be, e.g., from about 0.5 μg per square millimeter of surface area of the tubular member to about 10 μg per square millimeter of surface area of the tubular member.
  • [0019]
    The tubular member can include, e.g., an alloy, a bioresorbable metal, a metal oxide, a bioresorbable polymer or mixtures of these. In specific embodiments, the material is nitinol.
  • [0020]
    In some embodiments, the polymeric material is a thermoplastic and has an absolute molecular weight of greater than about 50,000, e.g., greater than about 100,000, greater than about 150,000 or greater than about 250,000.
  • [0021]
    In a specific embodiment, the polyol includes a polycaprolactone-polylactide copolymer, and the silsesquioxane includes 2-ethyl-2-[3-[[(heptaisobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxanyl)oxy]dimethylsilyl]-propoxy]methyl]-1,3-propanediol.
  • [0022]
    The polyol can have, e.g., an absolute molecular weight of from about 5,000 to about 50,000, from about 5,000 to about 25,000 or from about 10,000 to about 20,000.
  • [0023]
    In some embodiments, the polymeric material has a glass transition temperature of less than 100° C. In a specific embodiment, the polymeric material has a glass transition temperature of within about 10° C. of nominal human body temperature or within about 20° C. of nominal human body temperature.
  • [0024]
    The polymeric material can have, e.g., a storage modulus at 25° C. of less than 1,000 MPa, e.g., less than 750 MPa, less than 600 MPa or less than 500 MPa.
  • [0025]
    In another aspect, the invention features a method of treating a cavity or lumen in a mammal. The method includes inserting, into the lumen or cavity of the mammal, an implantable endoprosthesis including a tubular member having a coating. The coating includes a polymeric material that includes a reaction product of a polyol, an isocyanate and a silsesquioxane having at least two pendent hydroxyl group. The implantable endoprosthesis is expanded within the cavity or lumen of the mammal.
  • [0026]
    In some embodiments, the expanding is performed with a balloon in a vascular lumen.
  • [0027]
    In another aspect, the invention features a method of making a implantable endoprosthesis that includes a tubular member. The method includes coating the tubular member with a polymeric material that includes a reaction product of a polyol, an isocyanate and a silsesquioxane having at least two hydroxyl groups.
  • [0028]
    In some embodiments, the coating also includes a therapeutic agent.
  • [0029]
    The coating can be applied, e.g., by spraying a solution of the polymeric material onto the tubular member. The solution can contain, e.g., less than about 10 percent by weight of the polymeric material in a solvent. The solvent can be, e.g., tetrahydrofuran, toluene, methylene chloride or mixtures of these solvents.
  • [0030]
    In another aspect, the invention features an implantable endoprosthesis that includes a tubular member that is expandable from a first size to a second size and has a coating that includes a polymeric material and a therapeutic agent. During expansion of the implantable endoprosthesis from a first size to a second size, the coating does not substantially crack.
  • [0031]
    In some embodiments, the polymeric material includes a reaction product of a polyol, an isocyanate and a silsesquioxane having at least two pendent hydroxyl groups.
  • [0032]
    The tubular member can be, e.g., formed from a metal.
  • [0033]
    In another aspect, the invention features an implantable endoprosthesis that includes a tubular member that has a coating that includes a polymeric material and a therapeutic agent. During routine chemical sterilization of the implantable endoprosthesis with ethylene oxide, the coating does not slough off the tubular member.
  • [0034]
    The tubular member can be, e.g., a stent formed from a metal.
  • [0035]
    The polymeric material can include, e.g., a reaction product of a polyol, an isocyanate and a silsesquioxane having at least two pendent hydroxyl groups.
  • [0036]
    In another aspect, the invention features an implantable endoprosthesis that includes a tubular member that has a coating that includes a polymeric material that includes a reaction product of a polyol and an isocyanate.
  • [0037]
    In some embodiments, the reaction product also includes a silsesquioxane that has at least two pendent hydroxyl groups.
  • [0038]
    The coating can include a therapeutic agent.
  • [0039]
    In another aspect, the invention features an implantable endoprosthesis that includes a polymeric material that includes a reaction product of a polyol, an isocyanate and a silsesquioxane having at least two pendent hydroxyl groups. For example, the implantable endoprosthesis can include a tubular member, and the polymeric material can form a coating on the tubular member. In some embodiments, the tubular member is formed from a metal, e.g., one that degrades or corrodes in biological systems. For example, the metal that is degradable in biological systems can be magnesium or a magnesium alloy.
  • [0040]
    In another aspect, the invention features an implantable endoprosthesis that includes a tubular member. The tubular member includes a polymeric material that includes a reaction product of a polyol, a silsesquioxanes and an isocyanate. In some embodiments, the polymeric may include therapeutic agent dispersed therein.
  • [0041]
    Embodiments may have one or more of the following advantages. The coatings are flexible and resilient, enabling expansion of an implantable endoprosthesis having the coating from a first size to a second size larger than the first size without the coating substantially deforming, cracking and/or peeling during and/or after the expansion. The coatings can envelope a variety of materials, including metals, metal alloys, polymers and polymer alloys. The coatings allow for controlled release of therapeutic agents, e.g., paclitaxel. The rate of release of the therapeutic agent and/or the rate of degradation of the coating in biological systems can be controlled, and in many cases, predetermined, by adjusting ratios of the reaction products from which the coating is formed. The coatings are resistant to damage from sterilants, e.g., chemical sterilants, e.g., ethylene oxide; for example, coatings do not slough off the during routine chemical sterilization.
  • [0042]
    The term “polyol” as used herein includes any organic compound having on average two or more hydroxyl groups.
  • [0043]
    All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.
  • [0044]
    Other aspects, features, and advantages will be apparent from the description and drawings, and from the claims.
  • DESCRIPTION OF DRAWINGS
  • [0045]
    FIG. 1 is a perspective view of a metal stent having a coating.
  • [0046]
    FIGS. 2, 3 and 4 represent ladder-type 4, T8 cube-type 5 and cage-type 6 silsesquioxane structures, respectively.
  • [0047]
    FIG. 5 is a reaction scheme illustrating a method of preparing 1-(2-trans-cyclohexanediol)ethyl-3,5,7,9,11,13,15-isobutylpentacyclo-[9.5.1.13,9.15,15.17,13]-octasiloxane 7 from the corresponding epoxide, 1-[2-(3,4-epoxycyclohexyl)ethyl]-3,5,7,9,11,13,15-isobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxane 7′.
  • [0048]
    FIG. 6 is a structure of 2-ethyl-2-[3-[[(heptaisobutylpentacyclo-[9.5.1.13,9.15,1517,13]octasiloxanyl)oxy]dimethylsilyl]-propoxy]methyl]-1,3-propanediol 8.
  • [0049]
    FIG. 7 is a reaction scheme illustrating a method of preparing 1-(2,3-propanediol)propoxy-3,5,7,9,11,13,15-isobutylpentacyclo[9.5.1.13,9.15,15.17,13]-octasiloxane 9 from the corresponding epoxide, 1-(3-glycidyl)propoxy-3,5,7,9,11,13,15-isobutylpentacyclo-[9.5.1.13,9.15,15. 17,13]octasiloxane 9′.
  • [0050]
    FIG. 8 is a structure of 2-ethyl-2-[[3-[[(heptacyclopentylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxanyl)oxy]dimethylsilyl]propoxy]methyl]propane-1,3-diol 11.
  • [0051]
    FIG. 9 is a structure of a silsesquioxane 12 having 16 hydroxyl groups per molecule.
  • [0052]
    FIG. 10 is a reaction scheme illustrating a possible method of preparing partially condensed silsesquioxanes 2 and fully condensed silsesquioxanes 3 from an organo-trihydroxy silane 1.
  • [0053]
    FIG. 11 is a reaction scheme for producing a polymeric material from reacting polyethylene glycol 13, 1-(2-trans-cyclohexanediol)ethyl-3,5,7,9,11,13,15-isobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxane 7 and 4,4′-diphenylmethylene diisocyanate 14.
  • [0054]
    FIG. 12 is a reaction scheme for producing a polymeric material from reacting polycaprolactone diol 15, 2-ethyl-2-[3-[[(heptaisobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxanyl)oxy]dimethylsilyl]-propoxy]methyl]-1,3-propanediol 8 and 4,4′-diphenylmethylene diisocyanate 14.
  • [0055]
    FIG. 13 is a reaction scheme for producing a polymeric material from reacting polycyclooctene diol 16, 2-ethyl-2-[3-[[(heptaisobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxanyl)oxy]dimethylsilyl]-propoxy]methyl]-1,3-propanediol 8 and 4,4′-diphenylmethylene diisocyanate 14.
  • [0056]
    FIG. 14 is a reaction scheme for producing a polycaprolactone-polylactide random copolymer 19 from lactide 17 and caprolactone 18.
  • [0057]
    FIG. 15 is a reaction scheme for producing a polymeric material from reacting the polycaprolactone-polylactide random copolymer 19 of FIG. 15, 2-ethyl-2-[3-[[(heptaisobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxanyl)oxy]dimethylsilyl]-propoxy]methyl]-1,3-propanediol 8 and 4,4′-diphenylmethylene diisocyanate 14.
  • [0058]
    FIG. 16 is a possible reaction product 20 of the reaction scheme shown in FIG. 15.
  • [0059]
    FIG. 17 is a graph of Weight Percentage Remaining Versus Time (days) for seven different polymeric materials in the form of films, the polymeric materials being formed from the reaction shown in FIG. 15.
  • [0060]
    FIGS. 18A-18C illustrate delivery of the stent of FIG. 1 into a body lumen.
  • [0061]
    FIG. 19 is a schematic representation of a polymer 22 including a plurality of silsesquioxane units (SQ), each silsesquioxane having two pendent hydroxyl groups.
  • [0062]
    FIG. 20 is a structure of a partially condensed silsesquioxane 1,3,5,7,9,11,14-heptaisobutyltricyclo[7.3.3.15,11]heptasiloxane-endo-3,7,14-triol 23.
  • DETAILED DESCRIPTION
  • [0063]
    Referring to FIG. 1, a stent 40 includes bands 44 and connectors 46 that extend between and connect adjacent bands. During use, stent 40 is expanded from an initial, smaller transverse dimension to a larger transverse dimension to contact a wall of a lumen. Stent 40 is formed from a metal or a metal alloy, e.g., stainless steel, titanium, tantalum or Nitinol, and has a coating 14 that includes a therapeutic agent and a polymeric material that degrades in biological systems. The polymeric material includes a reaction product of a polyol, an isocyanate and a silsesquioxane having at least two pendent hydroxyl groups.
  • [0064]
    The polyol can be degradable, non-degradable, crystalline, partially crystalline or amorphous. The polyol can be, e.g., polyethylene glycol (PEG) polyol, polytetramethylene glycol polyol (polyTHF), polycyclooctene (PCO) polyol, trans-1,4-butadiene polyol, transisoprene polyol, polycaprolactone (PCL) polyol, polycaprolactone-polylactide copolymer polyol, e.g., polycaprolactone-polylactide random copolymer polyol, polycaprolactone-polyglycolide copolymer polyol, e.g., polycaprolactone-polyglycolide random copolymer polyol, polycaprolactone-polylactide-polyglycolide copolymer polyol, e.g., polycaprolactone-polylactide-polyglycolide random copolymer polyol, polylactide polyol, polycaprolactone-poly(β-hydroxybutyric acid) copolymer polyol, e.g., polycaprolactone-poly(β-hydroxybutyric acid) random copolymer polyol, poly(β-hydroxybutyric acid) polyol, polyester polyols, polyamide polyols, polyimide polyols, polyacrylate and polymethacrylate polyols, e.g., hydroxyl-terminated polyacrylate homopolymers and copolymers, polymethacrylate homopolymers and copolymers, (e.g., copolymers of methyl acrylate or methyl methacrylate and ethyl, propyl, or butyl acrylate or methacrylate), propane diols, butane diols, 1,6-hexanediol, 1,8-octanediol, neopentylglycol, glycerol, trimethylol propane, pentaerythritol, quinitol, mannitol, sorbitol, 1,4-trans-cyclohexane exodiol and 1,4-trans-cyclohexane endodiaol.
  • [0065]
    Polycaprolactone (PCL) polyols can be prepared, e.g., by initiating polymerization of caprolactone with a low molecular weight diol. Examples of low molecular weight diol initiators include C1-C10 alkyl diols, e.g., propane diol, butane diol or hexane diol.
  • [0066]
    Polycyclooctene (PCO) polyol, trans-1,4-butadiene polyol and transisoprene polyol can be made, e.g., by methods disclosed in European Polymer Journal, vol. 31, page 51(1995) and European Polymer Journal, vol. 31, page 339 (1997). Sartomer Company commercially provides a number of poly(diene) polyols, e.g., polybutadiene polyol.
  • [0067]
    Hydroxyl group functionalized polyacrylate and polymethacrylate polymers can be made, e.g., by methods disclosed in Macromolecules, vol. 37, pages 9694-9700 (2004).
  • [0068]
    Mixtures of polyols can be used.
  • [0069]
    In some embodiments, the polyol has only two pendent hydroxyl groups, and the hydroxyl groups are disposed at ends of the polyol.
  • [0070]
    The polyol can, e.g., have an absolute molecular weight of from about 5,000 to about 250,000, e.g., from about 5,000 to about 100,000 or from about 5,000 to about 80,000.
  • [0071]
    Isocyanates can be, e.g., aliphatic, cycloaliphatic, aromatic, or heterocyclic. For example, isocyanates include C4-C30 linear or branched alkyl diisocyanates and C8-C3 aryl diisocyanates. Optionally the alkyl or aryl groups can be substituted with one or more substituents such as C4-C10 tertiary alkyl, C1-C12 primary or secondary alkyl, C4-C10 tertiary alkoxy, C1-C12 primary or secondary alkoxy. The alkyl or aryl groups can also be substituted with a halogen, e.g., chlorine or bromine. Some specific isocyanates include 4,4′-diphenyl methylene diisocyanate, toluene-2,4-diisocyanate (TDI), toluene-2,6-diisocyanate, hexamethylene-1,6-diisocyanate (HDI), isophorone diisocyanate (IPDI), hydrogenated 4,4′-diphenylmethane diisocyanate, 1,3-bis-isocyanato-1-methylene ethylene benzene, ethylene diisocyanate, tetramethylene-1,4-diisoyanate, dodecane-1,12-diisocyanate, cyclobutane-1,3-diisocyanate, naphthylene-1,5-diisocyanate and triphenylmethane-4,4′,4″-triisocyanate.
  • [0072]
    Mixtures of isocyanates can be used.
  • [0073]
    Referring to FIGS. 2-4, silsesquioxanes, also known as T-resins, can exist in a variety of structural configurations, including ladder-type structures 4 (FIG. 2), T8 cube-type structures 5 (FIG. 3) and cage-type structures 6 (FIG. 4). Many silsesquioxanes are commercially available from either Hybrid Plastics™, Aldrich Chemical or from Reade Advanced Materials. Silsesquioxanes are discussed in “Silsesquioxanes, Bridging the Gap Between Polymers and Ceramics”, Chemfiles, Vol. 1, No. 6, 2001 (Aldrich Chemical), the entire contents of which is hereby incorporated by reference herein.
  • [0074]
    Referring to FIG. 5, one silsesquioxane is 1-(2-trans-cyclohexanediol)ethyl-3,5,7,9,11,13,15-isobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxane 7. It can be prepared from the corresponding epoxide, 1-[2-(3,4-epoxycyclohexyl)ethyl]-3,5,7,9,11,13,15-isobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxane 7′ by hydrolysis.
  • [0075]
    Referring now to FIG. 6, another silsesquioxane 2-ethyl-2-[3-[[(heptaisobutylpentacyclo-[9.5.1.13,9.15,15. 17,13]octasiloxanyl)oxy]dimethylsilyl]-propoxy]methyl]-1,3-propanediol 8.
  • [0076]
    Referring to FIG. 7, another silsesquioxane is 1-(2,3-propanediol)propoxy-3,5,7,9,11,13,15-isobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxane 9. It can be made from the corresponding epoxide, 1-(3-glycidyl)propoxy-3,5,7,9,11,13,15-isobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxane 9′.
  • [0077]
    FIG. 8 shows another silsesquioxane, namely, 2-ethyl-2-[[3-[[(heptacyclopentylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxanyl)oxy]-dimethylsilyl]propoxy]methyl]propane-1,3-diol 11. FIG. 9 illustrates a silsesquioxane 12 that has 16 hydroxyl groups per molecule.
  • [0078]
    Mixtures of silsesquioxanes can be used.
  • [0079]
    Referring to FIG. 10, one method of producing silsesquioxanes is via hydrolytic condensation of trifunctional organosilicon compounds, e.g., trihaloalkyl silanes or trialkoxyalkyl silanes. Hydrolysis of the trifunctional organosilicon compounds gives trihydroxy silanes 1, which upon condensation gives incompletely-condensed silsesquioxanes 2, which can be represented by formula [RSiO3/2]n(H2O)3n/2-x. Further condensation of 2 gives fully condensed silsesquioxanes 3, represented by formula [RSiO3/2]n.
  • [0080]
    The polymers can be synthesized, e.g., by a one-step condensation polymerization as described in “Shape Memory Polymers Based On Semicrystalline Thermoplastic Polyurethanes Bearing Nanostructured Hard Segments,” U.S. patent application Ser. No. ______, filed concurrently herewith. Generally, the polymers are prepared by charging a flask that has been purged with an inert gas, e.g., nitrogen, with the polyol. To the polyol is added a selected silsesquioxane in a solvent, e.g., toluene. The polyol-silsesquioxane mixture is heated to approximately 50-80° C. and maintained at that temperature. A selected isocyanate or mixture of isocyanates is/are added together with a catalyst, e.g., dibutyltin dilaurate. Temperature is maintained with stirring. Over time, the reaction mixture thickens. In a typical embodiment, the reaction mixture is maintained at the reaction temperature for 2 to 3 hours. In a typical embodiment, the thickened polymer solution is purified by precipitation by pouring the mixture into n-hexane.
  • [0081]
    Referring now to FIG. 11, in a specific embodiment, the polymeric material is prepared by reacting polyethylene glycol 13 together with 1-(2-trans-cyclohexanediol)ethyl-3,5,7,9,11,13,15-isobutylpentacyclo-[9.5.1.13,9.15,15.17,13]-octasiloxane 7 and 4,4′ diphenyl methylene diisocyanate 14.
  • [0082]
    Referring to FIG. 12, in another specific embodiment, the polymeric material is prepared by reacting polycaprolactone diol 15 together with 2-ethyl-2-[3-[[(heptaisobutylpentacyclo-[9.5.1.13,9.15,15. 17,13]octasiloxanyl)oxy]dimethylsilyl]-propoxy]methyl]-1,3-propanediol 8 and 4,4′-diphenylmethylene diisocyanate 14.
  • [0083]
    Referring to FIG. 13, in another specific embodiment, the polymeric material is prepared by reacting polycyclooctene diol 16 together with 2-ethyl-2-[3-[[(heptaisobutylpentacyclo-[9.5.1.13,9.15,1517,13]octasiloxanyl)oxy]dimethylsilyl]-propoxy]methyl]-1,3-propanediol 8 and 4,4′-diphenylmethylene diisocyanate 14.
  • [0084]
    Referring to FIGS. 14-16, a polycaprolactone-polylactide random copolymer 19 can be prepared by ring-opening condensation of D,L-lactide (meso) 17 and caprolactone 18. Random copolymer 19 can then be reacted together with 2-ethyl-2-[3-[[(heptaisobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxanyl)oxy]dimethylsilyl]-propoxy]methyl]-1,3-propanediol 8 and 4,4′-diphenylmethylene diisocyanate 14 to produce polymer 20 (FIG. 16). The polymer system enables systematic variation of ratio x/y, polyol degree of polymerization and total polymerization. For example, the ratio x/y can be between about 1 and about 20, the polyol degree of polymerization can be between about 2 and about 1000, and the total polymerization can be between about 3 to about 1000.
  • [0085]
    In general, the mole ratio of polyol to silsesquioxane to isocyanate can be, e.g., about 1:2:3, 1:5:6 or about 1:10:11. The weight ratio of the polyol to the silsesquioxane can be, e.g., from about 1:2 to about 1:30, from about 1:5 to about 1:25 or from about 1:5 to about 1:15.
  • [0086]
    In some embodiments, the polyol, the isocyante and/or the silsesquioxane is sufficiently hydrophilic so that the polymeric material forms a hydrogel when exposed to water.
  • [0087]
    The polymeric material can have, e.g., an absolute molecular weight of greater than about 25,000, e.g., greater than about 75,000, greater than about 85,000, greater than about 100,000, or greater than about 200,000. In some embodiments, the absolute molecular weight of the polymeric material is from about 25,000 to about 250,000, from about 25,000 to about 150,000 or from about 50,000 to about 150,000.
  • [0088]
    The polymeric material can have a polydispersity of, e.g., from about 1.1 to about 2.1, e.g., from about 1.3 to about 2.0, or from about 1.3 to about 1.8.
  • [0089]
    The polymeric material can be a thermoplastic or a thermoset. In some embodiments, the polymers have a glass transition temperature of less than 100° C., e.g., less than 80° C., less than 65° C., less than 50° C., less than 45° C., less than 35° C., less than 30° C., less than 20° C., less than 10° C., less than 0° C., less than −25° C. or less than −50° C. In one specific embodiment, the polymers have a glass transition temperature of within 25° C. of nominal human body temperature or within 10° C. of nominal human body temperature.
  • [0090]
    The polymeric material has, e.g., a storage modulus at 25° C. of less than 1,500 MPa, e.g., less than 1,250 MPa, less than 1,000 MPa, less than 900 MPa, less than 800 MPa, less than 500 MPa or less than 250 MPa.
  • [0091]
    The rate of degradation of the polymeric material can be controlled by adjusting the amount and type of silsesquioxane used, and by the amount and type of polyol. For example, the degradation rate can be decreased by increasing the amount of silsesquioxane used in forming the polymer, or by increasing the molecular weight of the polyol in the polymer. On the other hand, the degradation rate can be increased by increasing the number of hydrolyzable groups in the polyol.
  • [0092]
    Generally, in-vitro degradation tests of the any of the above polymers can be performed by making approximately 150 micron thick films, and then immersing the films in 0.01 M phosphate buffer solution (PBS) containing 0.138 M NaCl and 0.0027 M KCl at 37° C. Degradation is measured gravimetrically by following the percent of film mass remaining with time.
  • [0093]
    FIG. 17 summarizes the results of degradation tests conducted on approximately 150 micron thick films of seven polymers formed by the reaction of polycaprolactone-polylactide random copolymer 19, together with 2-ethyl-2-[3-[[(heptaisobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxanyl)oxy]dimethylsilyl]-propoxy]methyl]-1,3-propanediol 8 and 4,4′-diphenylmethylene diisocyanate 14. The tests were conducted in 0.01 M phosphate buffer solution (PBS) containing 0.138 M NaCl and 0.0027 M KCl at 37° C. The results showed that the polymer made from 33,000 molecular weight copolymer 19 and having a ratio of 19 to 8 of 1 to 15 was the slowest to degrade (line 6), while the polymer made from 20,000 molecular weight copolymer 19 and having a ratio of 19 to 8 of 1 to 8 was the fastest to degrade (line 3). The graph generally verifies the trend that the degradation rate can be decreased by increasing the amount of silsesquioxane used in forming the polymer, or by increasing the molecular weight of the polyol in the polymer.
  • [0094]
    In general, the therapeutic agent can be a genetic therapeutic agent, a non-genetic therapeutic agent, or cells. Therapeutic agents can be used singularly, or in combination. Therapeutic agents can be, for example, nonionic, or they may be anionic and/or cationic in nature. A preferred therapeutic agent is one that inhibits restenosis. A specific example of one such therapeutic agent that inhibits restenosis is paclitaxel.
  • [0095]
    The therapeutic agent can also be used, e.g., to treat and/or inhibit pain, encrustation of the endoprosthesis or sclerosing or necrosing of a treated lumen.
  • [0096]
    Exemplary non-genetic therapeutic agents include: (a) anti-thrombotic agents such as heparin, heparin derivatives, urokinase, PPack (dextrophenylalanine proline arginine chloromethylketone), and tyrosine; (b) anti-inflammatory agents, including non-steroidal anti-inflammatory agents (NSAID), such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine and mesalamine; (c) anti-neoplastic/antiproliferative/anti-miotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, angiopeptin, rapamycin (sirolimus), biolimus, tacrolimus, everolimus, monoclonal antibodies capable of blocking smooth muscle cell proliferation, and thymidine kinase inhibitors; (d) anesthetic agents such as lidocaine, bupivacaine and ropivacaine; (e) anti-coagulants such as D-Phe-Pro-Arg chloromethyl ketone, an RGD peptide-containing compound, heparin, hirudin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides; (f) vascular cell growth promoters such as growth factors, transcriptional activators, and translational promotors; (g) vascular cell growth inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; (h) protein kinase and tyrosine kinase inhibitors (e.g., tyrphostins, genistein, quinoxalines); (i) prostacyclin analogs; (j) cholesterol-lowering agents; (k) angiopoietins; (l) antimicrobial agents such as triclosan, cephalosporins, aminoglycosides and nitrofurantoin; (m) cytotoxic agents, cytostatic agents and cell proliferation affectors; (n) vasodilating agents; (o) agents that interfere with endogenous vasoactive mechanisms; (p) inhibitors of leukocyte recruitment, such as monoclonal antibodies; (q) cytokines, (r) hormones; and (s) antispasmodic agents, such as alibendol, ambucetamide, aminopromazine, apoatropine, bevonium methyl sulfate, bietamiverine, butaverine, butropium bromide, n-butylscopolammonium bromide, caroverine, cimetropium bromide, cinnamedrine, clebopride, coniine hydrobromide, coniine hydrochloride, cyclonium iodide, difemerine, diisopromine, dioxaphetyl butyrate, diponium bromide, drofenine, emepronium bromide, ethaverine, feclemine, fenalamide, fenoverine, fenpiprane, fenpiverinium bromide, fentonium bromide, flavoxate, flopropione, gluconic acid, guaiactamine, hydramitrazine, hymecromone, leiopyrrole, mebeverine, moxaverine, nafiverine, octamylamine, octaverine, oxybutynin chloride, pentapiperide, phenamacide hydrochloride, phloroglucinol, pinaverium bromide, piperilate, pipoxolan hydrochloride, pramiverin, prifinium bromide, properidine, propivane, propyromazine, prozapine, racefemine, rociverine, spasmolytol, stilonium iodide, sultroponium, tiemonium iodide, tiquizium bromide, tiropramide, trepibutone, tricromyl, trifolium, trimebutine, tropenzile, trospium chloride, xenylropium bromide, ketorolac, and pharmaceutically acceptable salts thereof.
  • [0097]
    Exemplary genetic therapeutic agents include anti-sense DNA and RNA as well as DNA coding for: (a) anti-sense RNA, (b) tRNA or rRNA to replace defective or deficient endogenous molecules, (c) angiogenic factors including growth factors such as acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor α and β, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α, hepatocyte growth factor and insulin-like growth factor, (d) cell cycle inhibitors including CD inhibitors, and (e) thymidine kinase (“TK”) and other agents useful for interfering with cell proliferation. Also of interest is DNA encoding for the family of bone morphogenic proteins (“BMP's”), including BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Currently preferred BMP's are any of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7. These dimeric proteins can be provided as homodimers, heterodimers, or combinations thereof, alone or together with other molecules. Alternatively, or in addition, molecules capable of inducing an upstream or downstream effect of a BMP can be provided. Such molecules include any of the “hedgehog” proteins, or the DNA's encoding them.
  • [0098]
    Vectors for delivery of genetic therapeutic agents include viral vectors such as adenoviruses, gutted adenoviruses, adeno-associated virus, retroviruses, alpha virus (Semliki Forest, Sindbis, etc.), lentiviruses, herpes simplex virus, replication competent viruses (e.g., ONYX-015) and hybrid vectors; and non-viral vectors such as artificial chromosomes and mini-chromosomes, plasmid DNA vectors (e.g., pCOR), cationic polymers (e.g., polyethyleneimine, polyethyleneimine (PEI)), graft copolymers (e.g., polyether-PEI and polyethylene oxide-PEI), neutral polymers PVP, SP1017 (SUPRATEK), lipids such as cationic lipids, liposomes, lipoplexes, nanoparticles, or micro particles, with and without targeting sequences such as the protein transduction domain (PTD).
  • [0099]
    Cells for use include cells of human origin (autologous or allogeneic), including whole bone marrow, bone marrow derived mono-nuclear cells, progenitor cells (e.g., endothelial progenitor cells), stem cells (e.g., mesenchymal, hematopoietic, neuronal), pluripotent stem cells, fibroblasts, myoblasts, satellite cells, pericytes, cardiomyocytes, skeletal myocytes or macrophage, or from an animal, bacterial or fungal source (xenogeneic), which can be genetically engineered, if desired, to deliver proteins of interest.
  • [0100]
    Any of the therapeutic agents described above can have more than a single function.
  • [0101]
    Generally, the coating includes, e.g., between about 1 percent by weight and about 35 by weight therapeutic agent, e.g., between about 5 percent by weight and about 30 percent by weight, between about 10 percent by weight and about 25 percent by weight or between about 15 percent by weight and about 20 percent by weight.
  • [0102]
    The coating can have a therapeutic agent elution profile that is, e.g., a function of the polymeric material. In particular, the elution profile can, e.g., be a function of the chemistry of the polymeric material, e.g., the monomers from which it is derived, the molecular weight of the polymeric material and a weight ratio of the monomers from which the polymeric material is derived. For example, in some embodiments, the rate of elution of the therapeutic agent from the coating can be a function of a ratio of the polyol component to the isocyanate portion. In some embodiments, adjusting the weight ratio of the monomers from which the polymeric material is derived enables “tuning” the elution rate to suite a particular need.
  • [0103]
    The coating can be configured to release substantially all of the therapeutic agent in a predetermined time. In some embodiments, the coating can be configured to release substantially all of the therapeutic agent in less than about 365 days, less than about 200 days, less than about 100 days, less than about 30 days, less than about 20 days, less than about 15 days or less than about 7 days while in blood at 37° C.
  • [0104]
    Coated tubular stent 40 can be made, e.g., by spraying a solution of the polymeric material onto an uncoated stent. Such spraying can be performed, e.g., during rotation of the stent to achieve a uniform coating thickness. The coating can be placed on by other methods, including dipping or electrostatically spraying.
  • [0105]
    The solution can, e.g., contain less than about 10 percent by weight of the polymeric material in a solvent. In some embodiments, the solution contains less than about 9 percent by weight, less than about 8 percent by weight, less than about 5 percent by weight, less than about 3 percent by weight, or less than about 1 percent by weight of the polymeric material in the solvent. Solvents include, e.g., tetrahydrofuran, toluene methylene chloride or mixtures of these solvents.
  • [0106]
    Coverage of the coating on the stent can be, e.g., from about 0.1 μg per square millimeter of surface area to about 10 μg per square millimeter of surface area. In some embodiments, the coverage is from about 0.5 μg to about 5 μg or from about 1 μg to about 2.5 μg.
  • [0107]
    In some embodiments, greater than 50 percent of the surface area of the stent is covered with coating 14, e.g., greater than 60 percent, greater than 75 percent, or greater than 90 percent of the surface area of the stent is covered with coating 14.
  • [0108]
    During expansion of the implantable endoprosthesis from an unexpanded size to an expanded size, the coating thins, but does not substantially crack. For example, before the stent 40 is expanded, the coating can have an average thickness of between about 5 μm and about 150 μm. In some embodiments, the coating has an average thickness of from about 10 μm to about 100 μm or from about 25 μm to about 75 μm.
  • [0109]
    In some embodiments, after expansion of stent 40 from the unexpanded size to the expanded size, the average thickness of the coating does not substantially decrease. While in other embodiment, after full expansion of stent 40 from the unexpanded size to the expanded size, the average thickness of coating decreases, e.g., by greater than about twenty percent. In some embodiments, the average thickness of the coating decreases by greater than about fifty percent, greater than about fifty-five percent, greater than about sixty percent, greater than about sixty-five percent, or greater than about ninety percent.
  • [0110]
    For example, after stent 40 is expanded, the coating can have an average thickness of, e.g., between about 1 μm and about 100 μm, between about 10 μm and 75 μm or between about 25 μm and 60 μm.
  • [0111]
    To treat a cavity or lumen in a human, e.g., a vascular lumen, e.g., a coronary artery, stent 40 is inserted into a lumen 100, and then expanded within the lumen. Referring particularly to FIGS. 18A and 18B, stent 40 is positioned over an inflatable balloon 102 disposed at a distal end of a delivery catheter 105. Referring particularly to FIGS. 18A, for delivery into the body, the balloon is initially in a small diameter deflated condition and stent 40 is in a small diameter condition over the balloon 102. Referring particularly to FIG. 18B, when the treatment site 104 is reached, the balloon is inflated by actuating the inflation apparatus 106, which provides outward radial force to expand stent 40. Referring particularly to FIG. 18C, after balloon 102 is deflated, the catheter 105 is removed from the body, while the stent 40 remains within lumen 100.
  • Other Embodiments
  • [0112]
    Other embodiments are within the scope of the claims.
  • [0113]
    The silsesquioxanes can be polymer-anchored. Referring to FIG. 19, a polymer 22 includes a plurality of silsesquioxane units (SQ). Each silsesquioxane unit has two pendent hydroxyl groups. Polymer 22 can be reacted with a polyol and an isocyanate to form a polymeric material that can form part of a coating.
  • [0114]
    Partially condensed silsesquioxanes can be used. For example, 1,3,5,7,9,11,14-heptaisobutyltricyclo[7.3.3.15,11]heptasiloxane-endo-3,7,14-triol 23 of FIG. 20 can be used.
  • [0115]
    The R substituent of any of the silsesquioxanes described herein can include a C1-C12 primary, secondary, or tertiary alkyl group. Exemplary R groups include methyl, isobutyl, isooctyl, cyclcopentyl, cyclohexyl, phenyl, and the like.
  • [0116]
    The implantable endoprosthesis can have non-circular transverse cross-sections. For example, transverse cross-sections can be polygonal, e.g., square, hexagonal or octagonal.
  • [0117]
    The metals used to form particular implantable endoprosthesis can be degradable in biological systems. Stents made of magnesium or magnesium alloys are examples of such endoprosthesis.
  • [0118]
    The coating can include more than a single layer. For example, the coating can include two layers, three layers or more layers, e.g., five layers.
  • [0119]
    The implantable endoprosthesis can include a tubular member formed from the polymeric material having a drug dispersed within. In addition, the tubular member can include a coating or coatings. The coating or coatings can include a therapeutic agent.
  • [0120]
    Block copolymers can be used to make the polymeric materials. The polymeric materials can be configured to be non-degradable in biological systems.
  • [0121]
    Chiral polyols, isocyanates and/or silsesquioxanes can be used. For example, D- or L-lactide can be used.
  • [0122]
    The implantable endoprosthesis can be a stent-graft or a covered stent.
  • [0123]
    The coated endoprosthesis can be configured for non-vascular lumens. For example, it can be configured for use in the esophagus or the prostate. Other lumens include biliary lumens, hepatic lumens, pancreatic lumens, uretheral lumens and ureteral lumens.
  • [0124]
    The implantable endoprosthesis can be formed from a plastic or plastic alloy, e.g., a degradable plastic or plastic alloy.
  • [0125]
    Any of the coatings described can also include fillers, e.g., boron nitride, silica, titanium dioxide, montmorillonite, clay, Kevlar®, aluminum nitride, barium and bismuth subcarbonate.
  • [0126]
    Any of the above coatings can by dyed or rendered radio-opaque.
  • [0127]
    The implantable endoprosthesis can include shapes in memory.
  • [0128]
    The implantable endoprosthesis can be self-expanding.
  • [0129]
    The polymeric material can include a reaction product of a polyol and an isocyanate, i.e., not including a silsesquioxane.

Claims (29)

  1. 1. (canceled)
  2. 2. The method of claim 23, wherein the coating further includes a therapeutic agent.
  3. 3. The method of claim 2, wherein the coating includes between about 1 percent by weight and about 35 by weight therapeutic agent.
  4. 4. The method of claim 2, wherein the therapeutic agent inhibits restenosis.
  5. 5. The method of claim 4, wherein the therapeutic agent that inhibits restenosis comprises paclitaxel.
  6. 6. The method of claim 2, wherein the polymeric material fully releases its therapeutic agent in less than seven days in blood at body temperature.
  7. 7. The method of claim 23, wherein the polymeric material fully degrades in less than 365 days in blood at body temperature.
  8. 8. The method of claim 23, wherein the polyol is selected from the group consisting of be polyethylene glycol, polycaprolactone polyol, polycyclooctene polyol, trans-1,4 butadiene polyol, transisoprene polyol, polynorbornene polyol, polymethacrylate copolymer polyol, polycaprolactone-polylactide copolymer polyol, polycaprolactone-polyglycolide copolymer polyol, polycaprolactone-polylactide-polyglycolide copolymer polyol, polylactide polyol, polycaprolactone-poly(β-hydroxybutyric acid) copolymer polyol, poly (β-hydroxybutyric acid) polyol, and mixtures thereof.
  9. 9. The method of claim 23, wherein the polyol has only two pendent hydroxyl groups, and wherein the hydroxyl groups are disposed at ends of the polyol.
  10. 10. The method of claim 23, wherein the isocyanate comprises a diisocyanate.
  11. 11. The method of claim 10, wherein the diisocyanate is selected from the group consisting of 4,4′-diphenyl methylene diisocyanate, toluene-2,4-diisocyanate, toluene-2,6-diisocyanate, hexamethylene-1,6-diisocyanate, isophorone diisocyanate, and hydrogenated 4,4′-diphenylmethylene diisocyanate, and mixtures thereof.
  12. 12. The method of claim 23, wherein the silsesquioxane selected from the group consisting 1-(2-trans-cyclohexanediol)ethyl-3,5,7,9,11,13,15-isobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxane, 2-ethyl-2-[3-[[(heptaisobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxanyl)oxy]dimethylsilyl]-propoxy methyl]propane-1,3-diol, 1-(2,3-propanediol)propoxy-3,5,7,9,11,13,15-isobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxane, 2-ethyl-2-[3-[[(heptaisobutylpentacyclo-[9.5.1.13,9.15,15.17,13]octasiloxanyl)oxy]dimethylsilyl]-propoxy]methyl]-1,3-propanediol, and mixtures thereof.
  13. 13. The method of claim 23, wherein a weight ratio of the polyol to the silsesquioxane is from about 1:2 to about 1:30.
  14. 14. The method of claim 23, wherein the coating has a thickness of between about 3 micron and about 50 micron before the implantable endoprosthesis is expanded.
  15. 15. The method of claim 23, wherein a coverage of the polymeric material on the tubular member is from about 0.1 μg per square millimeter of surface area of the tubular member to about 10 μg per square millimeter of surface area of the tubular member.
  16. 16. The method of claim 23, wherein the tubular member comprises a material selected from the group consisting of alloys, bioresorbable metals, metal oxides, bioresorbable polymers, and mixtures thereof.
  17. 17. The method of claim 23, wherein the polymeric material has an absolute molecular weight of greater than about 50,000.
  18. 18. (canceled)
  19. 19. The method of claim 23, wherein the polyol has an absolute molecular weight of from about 5,000 to about 20,000.
  20. 20. The method of claim 23, wherein the polymeric material has a glass transition temperature of less than 100° C.
  21. 21. The method of claim 23, wherein the polymeric material has a glass transition temperature of within about 10° C. of nominal human body temperature.
  22. 22. The method of claim 23, wherein the polymeric material has a storage modulus at 25° C. of less than 1,000 MPa.
  23. 23. A method of treating a cavity or lumen in a mammal, the method comprising:
    implanting, into the lumen or cavity of the mammal, an endoprosthesis comprising a tubular member having a coating comprising a polymeric material including a reaction product of a polyol, an isocyanate and a silsesquioxane having at least two pendent hydroxyl groups.
  24. 24. The method of claim 23, wherein the method further includes expanding the endoprosthesis.
  25. 25. The method of claim 23, wherein the lumen is a vascular lumen.
  26. 26-37. (canceled)
  27. 38. The method of claim 24, wherein the expanding in performed with a balloon.
  28. 39. The method of claim 24, wherein the endoprosthesis is self-expanding.
  29. 40. The method of claim 2, wherein the therapeutic agent comprises everolimus.
US13053461 2002-10-11 2011-03-22 Endoprostheses Abandoned US20110172753A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US48832303 true 2003-07-18 2003-07-18
US48859003 true 2003-07-18 2003-07-18
US10683314 US20050010275A1 (en) 2002-10-11 2003-10-10 Implantable medical devices
US10958435 US7794494B2 (en) 2002-10-11 2004-10-05 Implantable medical devices
US11111509 US7976936B2 (en) 2002-10-11 2005-04-21 Endoprostheses
US13053461 US20110172753A1 (en) 2003-07-18 2011-03-22 Endoprostheses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13053461 US20110172753A1 (en) 2003-07-18 2011-03-22 Endoprostheses
US15185851 US20160296677A1 (en) 2003-07-18 2016-06-17 Endoprostheses

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11111509 Division US7976936B2 (en) 2002-10-11 2005-04-21 Endoprostheses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15185851 Continuation US20160296677A1 (en) 2002-10-11 2016-06-17 Endoprostheses

Publications (1)

Publication Number Publication Date
US20110172753A1 true true US20110172753A1 (en) 2011-07-14

Family

ID=37074645

Family Applications (3)

Application Number Title Priority Date Filing Date
US11111509 Active 2027-11-28 US7976936B2 (en) 2002-10-11 2005-04-21 Endoprostheses
US13053461 Abandoned US20110172753A1 (en) 2002-10-11 2011-03-22 Endoprostheses
US15185851 Pending US20160296677A1 (en) 2002-10-11 2016-06-17 Endoprostheses

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11111509 Active 2027-11-28 US7976936B2 (en) 2002-10-11 2005-04-21 Endoprostheses

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15185851 Pending US20160296677A1 (en) 2002-10-11 2016-06-17 Endoprostheses

Country Status (5)

Country Link
US (3) US7976936B2 (en)
EP (1) EP1874371B1 (en)
JP (1) JP5255434B2 (en)
DE (1) DE602006006994D1 (en)
WO (1) WO2006115847A3 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713297B2 (en) 1998-04-11 2010-05-11 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
WO2003002243A3 (en) 2001-06-27 2004-03-04 Remon Medical Technologies Ltd Method and device for electrochemical formation of therapeutic species in vivo
US7794494B2 (en) 2002-10-11 2010-09-14 Boston Scientific Scimed, Inc. Implantable medical devices
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US20070224235A1 (en) 2006-03-24 2007-09-27 Barron Tenney Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US8771343B2 (en) 2006-06-29 2014-07-08 Boston Scientific Scimed, Inc. Medical devices with selective titanium oxide coatings
CA2659761A1 (en) 2006-08-02 2008-02-07 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
JP2010503469A (en) 2006-09-14 2010-02-04 ボストン サイエンティフィック リミテッド Medical device having a drug eluting coating
CA2663271A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Bioerodible endoprostheses and methods of making the same
ES2368125T3 (en) 2006-09-15 2011-11-14 Boston Scientific Scimed, Inc. bioerodible endoprostheses biostable inorganic layers.
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
EP2959925A1 (en) 2006-09-15 2015-12-30 Boston Scientific Limited Medical devices and methods of making the same
US7955382B2 (en) 2006-09-15 2011-06-07 Boston Scientific Scimed, Inc. Endoprosthesis with adjustable surface features
CA2663762A1 (en) 2006-09-18 2008-03-27 Boston Scientific Limited Endoprostheses
WO2008036549A3 (en) * 2006-09-18 2008-05-22 Liliana Atanasoska Medical devices
WO2008063356A3 (en) * 2006-10-30 2009-04-09 Poly Med Inc Suture-specific coatings for modulated release of biocative agents
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US20080132988A1 (en) * 2006-12-01 2008-06-05 Scimed Life Systems, Inc. Balloon geometry for delivery and deployment of shape memory polymer stent with flares
DE602007010669D1 (en) 2006-12-28 2010-12-30 Boston Scient Ltd hear it
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
WO2009020520A1 (en) 2007-08-03 2009-02-12 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US20090227026A1 (en) * 2008-02-14 2009-09-10 Rapoport H Scott Tissue engineering scaffolds
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
WO2009132176A3 (en) 2008-04-24 2010-09-02 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
WO2009155328A3 (en) 2008-06-18 2010-09-16 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US20100217370A1 (en) * 2009-02-20 2010-08-26 Boston Scientific Scimed, Inc. Bioerodible Endoprosthesis
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
US20100292776A1 (en) * 2009-05-14 2010-11-18 Boston Scientific Scimed, Inc. Bioerodible Endoprosthesis
US20110022158A1 (en) 2009-07-22 2011-01-27 Boston Scientific Scimed, Inc. Bioerodible Medical Implants
US20110160839A1 (en) * 2009-12-29 2011-06-30 Boston Scientific Scimed, Inc. Endoprosthesis
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
WO2011119430A1 (en) * 2010-03-26 2011-09-29 Boston Scientific Scimed, Inc. Endoprosthesis
US9249254B2 (en) * 2010-04-22 2016-02-02 Syracuse University Polyhedral oligomeric silsesquioxane polyurethanes
US8709072B2 (en) 2010-05-13 2014-04-29 Boston Scientific Scimed, Inc. Endoprosthesis
WO2011143284A1 (en) * 2010-05-14 2011-11-17 Boston Scientific Scimed, Inc. Endoprosthesis

Citations (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3383336A (en) * 1966-06-27 1968-05-14 Kuyama Hiroshi Resinous insoluble reaction products
US3459725A (en) * 1964-01-17 1969-08-05 Montedison Spa High molecular weight unsaturated hydrocarbon homopolymers and process for preparing them
US3563973A (en) * 1965-03-04 1971-02-16 Radiation Applic Inc Articles with polymeric memory and method of constructing same
US4080357A (en) * 1976-06-07 1978-03-21 Shell Oil Company Multicomponent halogenated thermoplastic-block copolymer-polymer blends
US4503569A (en) * 1983-03-03 1985-03-12 Dotter Charles T Transluminally placed expandable graft prosthesis
US4531933A (en) * 1982-12-07 1985-07-30 C. R. Bard, Inc. Helical ureteral stent
US4893623A (en) * 1986-12-09 1990-01-16 Advanced Surgical Intervention, Inc. Method and apparatus for treating hypertrophy of the prostate gland
US4950258A (en) * 1988-01-28 1990-08-21 Japan Medical Supply Co., Ltd. Plastic molded articles with shape memory property
US4990155A (en) * 1989-05-19 1991-02-05 Wilkoff Howard M Surgical stent method and apparatus
US5007926A (en) * 1989-02-24 1991-04-16 The Trustees Of The University Of Pennsylvania Expandable transluminally implantable tubular prosthesis
US5037427A (en) * 1987-03-25 1991-08-06 Terumo Kabushiki Kaisha Method of implanting a stent within a tubular organ of a living body and of removing same
US5089005A (en) * 1987-08-13 1992-02-18 Terumo Kabushiki Kaisha Catheter for the introduction of an expandable member
US5100429A (en) * 1989-04-28 1992-03-31 C. R. Bard, Inc. Endovascular stent and delivery system
US5187110A (en) * 1990-10-05 1993-02-16 Allied-Signal Inc. Field effect transistor-bipolar transistor darlington pair
US5278237A (en) * 1991-08-09 1994-01-11 Daicel-Huls Ltd. Sculpturing resin composition and process for sculpturing a sculptured product
US5282854A (en) * 1989-10-11 1994-02-01 Daikin Industries Ltd. Fluorine-containing block copolymer and artificial lens comprising the same
US5395882A (en) * 1992-09-24 1995-03-07 Rohm Gmbh Chemische Fabrik Light-scattering polystyrene molding compounds, and molded articles produced therefrom
US5421955A (en) * 1991-10-28 1995-06-06 Advanced Cardiovascular Systems, Inc. Expandable stents and method for making same
US5496311A (en) * 1988-10-28 1996-03-05 Boston Scientific Corporation Physiologic low stress angioplasty
US5506300A (en) * 1985-01-04 1996-04-09 Thoratec Laboratories Corporation Compositions that soften at predetermined temperatures and the method of making same
US5607467A (en) * 1990-09-14 1997-03-04 Froix; Michael Expandable polymeric stent with memory and delivery apparatus and method
US5645559A (en) * 1992-05-08 1997-07-08 Schneider (Usa) Inc Multiple layer stent
US5741333A (en) * 1995-04-12 1998-04-21 Corvita Corporation Self-expanding stent for a medical device to be introduced into a cavity of a body
US5755769A (en) * 1992-03-12 1998-05-26 Laboratoire Perouse Implant Expansible endoprosthesis for a human or animal tubular organ, and fitting tool for use thereof
US5762625A (en) * 1992-09-08 1998-06-09 Kabushikikaisha Igaki Iryo Sekkei Luminal stent and device for inserting luminal stent
US5766188A (en) * 1995-05-08 1998-06-16 Kabushikikaisha Igaki Iryo Sekkei Medical suturing material
US5769883A (en) * 1991-10-04 1998-06-23 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US5776162A (en) * 1997-01-03 1998-07-07 Nitinol Medical Technologies, Inc. Vessel implantable shape memory appliance with superelastic hinged joint
US5876432A (en) * 1994-04-01 1999-03-02 Gore Enterprise Holdings, Inc. Self-expandable helical intravascular stent and stent-graft
US5880240A (en) * 1996-04-03 1999-03-09 Arakawa Chemical Industries, Ltd. Alkyl-containing porous resin, process for its preparation and its use
US5889118A (en) * 1996-06-03 1999-03-30 Minnesota Mining And Manufacturing Company Thermomorphic "smart" pressure sensitive adhesives
US5900444A (en) * 1996-10-08 1999-05-04 Zamore; Alan Irradiation conversion of thermoplastic to thermoset polyurethane
US5900246A (en) * 1993-03-18 1999-05-04 Cedars-Sinai Medical Center Drug incorporating and releasing polymeric coating for bioprosthesis
US5908918A (en) * 1996-07-17 1999-06-01 Chronopol, Inc. Impact modified polylactide
US5910357A (en) * 1996-07-12 1999-06-08 Nitto Denko Corporation Separation membrane and method of producing the same, and shape memory polymer composition
US5928217A (en) * 1996-04-09 1999-07-27 Endocare, Inc. Urological stent therapy system and method
US5935506A (en) * 1995-10-24 1999-08-10 Biotronik Meβ- und Therapiegerate GmbH & Co. Ingenieurburo Berlin Method for the manufacture of intraluminal stents of bioresorbable polymeric material
US6024764A (en) * 1997-08-19 2000-02-15 Intermedics, Inc. Apparatus for imparting physician-determined shapes to implantable tubular devices
US6033413A (en) * 1998-04-20 2000-03-07 Endocare, Inc. Stent delivery system
US6045568A (en) * 1991-03-08 2000-04-04 Igaki; Keiji Luminal stent, holding structure therefor and device for attaching luminal stent
US6086204A (en) * 1999-09-20 2000-07-11 Magnante; Peter C. Methods and devices to design and fabricate surfaces on contact lenses and on corneal tissue that correct the eye's optical aberrations
US6086610A (en) * 1996-10-22 2000-07-11 Nitinol Devices & Components Composite self expanding stent device having a restraining element
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6183248B1 (en) * 1998-11-30 2001-02-06 Muhammad Chishti System and method for releasing tooth positioning appliances
US6200335B1 (en) * 1997-03-31 2001-03-13 Kabushikikaisha Igaki Iryo Sekkei Stent for vessel
US6217609B1 (en) * 1998-06-30 2001-04-17 Schneider (Usa) Inc Implantable endoprosthesis with patterned terminated ends and methods for making same
US6241691B1 (en) * 1997-12-05 2001-06-05 Micrus Corporation Coated superelastic stent
US6248129B1 (en) * 1990-09-14 2001-06-19 Quanam Medical Corporation Expandable polymeric stent with memory and delivery apparatus and method
US20020007222A1 (en) * 2000-04-11 2002-01-17 Ashvin Desai Method and apparatus for supporting a body organ
US20020015519A1 (en) * 1998-12-11 2002-02-07 Lord Corporation Fiber substrate adhesion and coatings by contact metathesis polymerization
US6348064B1 (en) * 2000-09-01 2002-02-19 Angiolink Corporation Wound site management and wound closure device
US6364904B1 (en) * 1999-07-02 2002-04-02 Scimed Life Systems, Inc. Helically formed stent/graft assembly
US6368346B1 (en) * 1999-06-03 2002-04-09 American Medical Systems, Inc. Bioresorbable stent
US20020055787A1 (en) * 1998-10-15 2002-05-09 Charles D. Lennox Treating urinary retention
US6388043B1 (en) * 1998-02-23 2002-05-14 Mnemoscience Gmbh Shape memory polymers
US6413273B1 (en) * 1998-11-25 2002-07-02 Israel Aircraft Industries Ltd. Method and system for temporarily supporting a tubular organ
US6517569B2 (en) * 1998-09-14 2003-02-11 Endocare, Inc. Insertion device for stents and methods for use
US6517570B1 (en) * 1994-08-31 2003-02-11 Gore Enterprise Holdings, Inc. Exterior supported self-expanding stent-graft
US20030030530A1 (en) * 2001-07-10 2003-02-13 Friwo Geraetebau Gmbh Charging unit for a contactless transfer of electric power as well as a power absorbing device and a charging system
US20030033001A1 (en) * 2001-02-27 2003-02-13 Keiji Igaki Stent holding member and stent feeding system
US20030040803A1 (en) * 2001-08-23 2003-02-27 Rioux Robert F. Maintaining an open passageway through a body lumen
US6538089B1 (en) * 1999-02-05 2003-03-25 Forskarpatent I Syd Ab Gels with a shape memory
US20030060793A1 (en) * 2001-07-24 2003-03-27 Topolkaraev Vasily A. Disposable products having humidity activated materials with shape-memory
US6596818B1 (en) * 1996-10-08 2003-07-22 Alan M. Zamore Irradiation conversion of thermoplastic to thermoset polymers
US6679605B2 (en) * 2000-05-22 2004-01-20 Medennium, Inc. Crystalline polymeric compositions for ophthalmic devices
US20040015261A1 (en) * 2000-08-28 2004-01-22 Hofmann Gregory J. Shape memory polymer or alloy ophthalmic lens mold and methods of forming ophthalmic products
US20040014929A1 (en) * 2002-04-18 2004-01-22 Mnemoscience Gmbh Polyester urethanes
US20040015187A1 (en) * 2002-04-18 2004-01-22 Mnemoscience Corporation Biodegradable shape memory polymeric sutures
US20040024143A1 (en) * 2002-04-18 2004-02-05 Mnemoscience Gmbh Interpenetrating networks
US20040024098A1 (en) * 2002-07-30 2004-02-05 Mather Patrick T. Nonionic telechelic polymers incorporating polyhedral oligosilsesquioxane (POSS) and uses thereof
US20040030062A1 (en) * 2002-05-02 2004-02-12 Mather Patrick T. Castable shape memory polymers
US20040060428A1 (en) * 2002-10-01 2004-04-01 Sanderson Paul H. Sponson tow plate-mounted helicopter armament apparatus and associated methods
US20040116641A1 (en) * 2002-10-11 2004-06-17 Mather Patrick T. Shape memory polymers based on semicrystalline thermoplastic polyurethanes bearing nanostructured hard segments
US20040122184A1 (en) * 2002-10-11 2004-06-24 Mather Patrick T. Crosslinked polycyclooctene
US6858680B2 (en) * 1999-07-20 2005-02-22 Aortech Biomaterials Pty Ltd Shape memory polyurethane or polyurethane-urea polymers
USRE38711E1 (en) * 1991-03-08 2005-03-15 Kabushikikaisha Igaki Iryo Sekkei Luminal stent, holding structure therefor and device for attaching luminal stent
US6958212B1 (en) * 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US7008979B2 (en) * 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
US7066952B2 (en) * 1998-09-08 2006-06-27 Kabushikikaisha Igaki Iryo Sekkei Method for manufacturing yarn for vessel stent
US7070615B1 (en) * 2000-03-13 2006-07-04 Keiji Igaki Linear material for blood vessel stent and blood vessel stent utilizing same
US7198639B2 (en) * 2002-09-13 2007-04-03 Bausch & Lomb Incorporated Polysilsesquioxane containing polymeric compositions
US7367990B2 (en) * 2002-09-25 2008-05-06 Kabushikikaisha Igaki Iryo Sekkei Thread for vascular stent and vascular stent using the thread
US7473273B2 (en) * 2002-01-22 2009-01-06 Medtronic Vascular, Inc. Stent assembly with therapeutic agent exterior banding
US7498042B2 (en) * 2000-11-30 2009-03-03 Kyoto Medical Planning Co., Ltd. Stent for blood vessel and material for stent for blood vessel
US7670302B2 (en) * 2001-12-18 2010-03-02 Boston Scientific Scimed, Inc. Super elastic guidewire with shape retention tip

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6198254A (en) 1984-10-19 1986-05-16 Raychem Corp Prosthetic stent
JP2594535B2 (en) 1984-11-30 1997-03-26 サントリー株式会社 High expression vector and its use
DE3650342T2 (en) 1985-01-04 1995-11-02 Thoratec Lab Corp A process for producing a molded article with shape-memory properties and some of the obtained moldings.
US4612241A (en) * 1985-06-12 1986-09-16 E. I. Du Pont De Nemours And Company Impact resistant composites with elastomeric fibers
JPS63145325A (en) 1986-12-08 1988-06-17 Daiseru Hiyurusu Kk Resin material for shaping of model
US4839443A (en) 1987-02-04 1989-06-13 Chisso Corporation Polysiloxane containing hydroxyl groups and a silicone-modified polyurethane using the same
JPH088933B2 (en) * 1987-07-10 1996-01-31 日本ゼオン株式会社 Catheter - Tel
US4942212A (en) 1988-01-20 1990-07-17 Dainichiseika Color & Chemicals Mfg. Co., Ltd. Polyurethane resin and heat-sensitive recording medium
DE3817624A1 (en) 1988-05-25 1989-11-30 Bayer Ag Mixtures prepared from a metastable amorphous teilkirstallinen, thermoplastics
US4874360A (en) * 1988-07-01 1989-10-17 Medical Engineering Corporation Ureteral stent system
JP2502132B2 (en) * 1988-09-30 1996-05-29 三菱重工業株式会社 Shape memory polyurethane elastomer - shaped body
US4962178A (en) * 1988-11-03 1990-10-09 Ciba-Geigy Corporation Novel polysiloxane-polyurethanes and contact lens thereof
CA2002408A1 (en) 1988-11-11 1990-05-11 Shoji Suzuki Structural material and its application
JPH0832766B2 (en) 1988-12-07 1996-03-29 帝人株式会社 Shape memory crosslinked polymer molded article and manufacturing method thereof
US5189110A (en) * 1988-12-23 1993-02-23 Asahi Kasei Kogyo Kabushiki Kaisha Shape memory polymer resin, composition and the shape memorizing molded product thereof
EP0385443A3 (en) 1989-02-28 1990-10-10 Daikin Industries, Limited Polymer material having shape memory characteristics
US5062829A (en) * 1989-03-17 1991-11-05 Carter Holt Harvey Plastic Products Group Limited Relates to devices for administering a substance such as a drug or chemical or the like
JPH0321613A (en) 1989-06-19 1991-01-30 Nippon Unicar Co Ltd Shape-memorizing elastomer
US5147385A (en) * 1989-11-01 1992-09-15 Schneider (Europe) A.G. Stent and catheter for the introduction of the stent
JPH03255151A (en) * 1989-12-28 1991-11-14 Daicel Huels Ltd Carving material, and polyoctenamer resin composition used therefor
US5545208A (en) * 1990-02-28 1996-08-13 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5064435A (en) 1990-06-28 1991-11-12 Schneider (Usa) Inc. Self-expanding prosthesis having stable axial length
US5163952A (en) 1990-09-14 1992-11-17 Michael Froix Expandable polymeric stent with memory and delivery apparatus and method
US5665822A (en) * 1991-10-07 1997-09-09 Landec Corporation Thermoplastic Elastomers
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5964744A (en) * 1993-01-04 1999-10-12 Menlo Care, Inc. Polymeric medical device systems having shape memory
US5466242A (en) 1994-02-02 1995-11-14 Mori; Katsushi Stent for biliary, urinary or vascular system
US20020156523A1 (en) * 1994-08-31 2002-10-24 Lilip Lau Exterior supported self-expanding stent-graft
WO1996025897A3 (en) * 1995-02-22 1996-11-21 Menlo Care Inc Covered expanding mesh stent
DE69622231T2 (en) * 1995-03-01 2002-12-05 Scimed Life Systems Inc Longitudinal Flexible and expandable stent
BE1009277A3 (en) 1995-04-12 1997-01-07 Corvita Europ Guardian self-expandable medical device introduced in cavite body, and method of preparation.
US5954744A (en) * 1995-06-06 1999-09-21 Quanam Medical Corporation Intravascular stent
US5674242A (en) * 1995-06-06 1997-10-07 Quanam Medical Corporation Endoprosthetic device with therapeutic compound
US5676685A (en) * 1995-06-22 1997-10-14 Razavi; Ali Temporary stent
DE69526857T2 (en) * 1995-11-27 2003-01-02 Schneider Europ Gmbh Buelach Stent for use in a physical passage
US6702846B2 (en) * 1996-04-09 2004-03-09 Endocare, Inc. Urological stent therapy system and method
US5800516A (en) * 1996-08-08 1998-09-01 Cordis Corporation Deployable and retrievable shape memory stent/tube and method
US6072154A (en) 1996-09-05 2000-06-06 Medtronic, Inc. Selectively activated shape memory device
US5955559A (en) * 1996-09-17 1999-09-21 Shell Oil Company Cast polyurethane elastomers containing low polarity amine curing agents
US6315791B1 (en) 1996-12-03 2001-11-13 Atrium Medical Corporation Self-expanding prothesis
US7662409B2 (en) * 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
RU2215542C2 (en) 1998-02-23 2003-11-10 Массачусетс Инститьют Оф Текнолоджи Biodecomposing polymers able recovery of form
EP1062273A1 (en) 1998-03-11 2000-12-27 The Dow Chemical Company STRUCTURES AND FABRICATED ARTICLES HAVING SHAPE MEMORY MADE FROM $g(a)-OLEFIN/VINYL OR VINYLIDENE AROMATIC AND/OR HINDERED ALIPHATIC VINYL OR VINYLIDENE INTERPOLYMERS
US8182527B2 (en) * 2001-05-07 2012-05-22 Cordis Corporation Heparin barrier coating for controlled drug release
US6312461B1 (en) 1998-08-21 2001-11-06 John D. Unsworth Shape memory tubular stent
US20080086214A1 (en) * 1998-08-31 2008-04-10 Wilson-Cook Medical Inc. Medical device having a sleeve valve with bioactive agent
US6162231A (en) 1998-09-14 2000-12-19 Endocare, Inc. Stent insertion device
US5997563A (en) 1998-09-28 1999-12-07 Medtronic, Inc. Implantable stent having variable diameter
JP2000119465A (en) 1998-10-13 2000-04-25 Tokai Rubber Ind Ltd Shape-memory resin composition and shape-memory active made thereof
US6281262B1 (en) 1998-11-12 2001-08-28 Takiron Co., Ltd. Shape-memory, biodegradable and absorbable material
US6478773B1 (en) 1998-12-21 2002-11-12 Micrus Corporation Apparatus for deployment of micro-coil using a catheter
US6623823B1 (en) 1998-12-31 2003-09-23 Ethicon, Inc. Radiopaque polymer coating
US6530950B1 (en) * 1999-01-12 2003-03-11 Quanam Medical Corporation Intraluminal stent having coaxial polymer member
JP2000319423A (en) 1999-05-12 2000-11-21 Showa Highpolymer Co Ltd Flexible material
DE60004817D1 (en) 1999-05-24 2003-10-02 California Inst Of Techn Imidazolidine containing metal carbene catalysts for metathesis
JP3068610B1 (en) 1999-06-10 2000-07-24 多摩川精機株式会社 The core axis motor
JP4100831B2 (en) 1999-07-16 2008-06-11 不二サッシ株式会社 Building of the gap covering device having a seismic isolation structure
US6485507B1 (en) 1999-07-28 2002-11-26 Scimed Life Systems Multi-property nitinol by heat treatment
US6287326B1 (en) * 1999-08-02 2001-09-11 Alsius Corporation Catheter with coiled multi-lumen heat transfer extension
US6908624B2 (en) * 1999-12-23 2005-06-21 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
JP3068611U (en) 1999-10-29 2000-05-16 株式会社タカラ The magnetic pen for a magnetic drawing board
US6695865B2 (en) 2000-03-20 2004-02-24 Advanced Bio Prosthetic Surfaces, Ltd. Embolic protection device
JP3654627B2 (en) 2000-04-20 2005-06-02 和明 光藤 Stent
WO2001091822A1 (en) 2000-05-31 2001-12-06 Mnemoscience Gmbh Shape memory thermoplastics and polymer networks for tissue engineering
US6652576B1 (en) 2000-06-07 2003-11-25 Advanced Cardiovascular Systems, Inc. Variable stiffness stent
WO2002019591A3 (en) 2000-08-31 2002-09-12 Millimetrix Broadband Networks Improved spatial spectral efficiency for wireless rings and network of links in millimeter wave (mmw) communication systems
US6939377B2 (en) * 2000-08-23 2005-09-06 Thoratec Corporation Coated vascular grafts and methods of use
US6607553B1 (en) 2000-11-17 2003-08-19 B. Braun Medical, Inc. Method for deploying a thermo-mechanically expandable stent
CA2435809A1 (en) * 2001-01-24 2002-08-01 Johnson & Johnson Vision Care, Inc. Shape memory styrene copolymer
WO2002083786A1 (en) 2001-04-11 2002-10-24 Cheong Seok Hong Shape memory rubber composition
US6653365B2 (en) * 2001-05-01 2003-11-25 Pentron Clinical Technologies, Llc Dental composite materials and method of manufacture thereof
US6627673B2 (en) 2001-07-24 2003-09-30 Kimberly-Clark Worldwide, Inc. Methods of making humidity activated materials having shape-memory
DE10152146A1 (en) 2001-10-25 2003-05-22 Ticona Gmbh A method of reducing the toughness mechanically machined plastic moldings and the use thereof
DE10156619A1 (en) * 2001-11-17 2003-05-28 Creavis Tech & Innovation Gmbh A process for preparing functionalized oligomeric silsesquioxanes as well as their use
US6860601B2 (en) * 2002-02-06 2005-03-01 John H. Shadduck Adaptive optic lens system and method of use
DE10208211A1 (en) * 2002-02-26 2003-09-11 Mnemoscience Gmbh polymeric networks
DE10215858A1 (en) 2002-04-10 2004-03-18 Mnemoscience Gmbh Method of treating hair with shape memory polymers
JP2005529095A (en) 2002-04-10 2005-09-29 ネモサイエンス、ゲーエムベーハーMnemoscience Gmbh How to achieve the shape memory effect in hair
DE10228120B4 (en) 2002-06-24 2004-07-08 Mnemoscience Gmbh Means and methods for treating hair with shape memory polymers
WO2004006885A3 (en) 2002-07-10 2004-03-18 Andreas Lendlein Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect
US7794494B2 (en) * 2002-10-11 2010-09-14 Boston Scientific Scimed, Inc. Implantable medical devices
US7524914B2 (en) 2002-10-11 2009-04-28 The University Of Connecticut Shape memory polymers based on semicrystalline thermoplastic polyurethanes bearing nanostructured hard segments
WO2004033539A1 (en) 2002-10-11 2004-04-22 University Of Connecticut Blends of amorphous and semicrystalline polymers having shape memory properties
US6641899B1 (en) * 2002-11-05 2003-11-04 International Business Machines Corporation Nonlithographic method to produce masks by selective reaction, articles produced, and composition for same
US7311727B2 (en) * 2003-02-05 2007-12-25 Board Of Trustees Of The University Of Arkansas Encased stent
CN1750813A (en) 2003-02-19 2006-03-22 尼莫科学有限公司 Self-expanding device for the gastrointestinal or urogenitalarea
DE10316573A1 (en) 2003-04-10 2004-11-04 Mnemoscience Gmbh Blends with shape-memory properties
WO2004110515A1 (en) 2003-06-13 2004-12-23 Mnemoscience Gmbh Biodegradable stents
JP4379044B2 (en) * 2003-08-22 2009-12-09 株式会社カネカ Indwelling stent
JP2005102953A (en) 2003-09-30 2005-04-21 Tomii Kk Orthodontic appliance
GB0401202D0 (en) 2004-01-20 2004-02-25 Ucl Biomedica Plc Polymer for use in conduits and medical devices
US20090171453A1 (en) * 2007-12-28 2009-07-02 Adams Tara K Drug Coated Stent Having a Surface Treatment and Method of Manufacturing
US20090306769A1 (en) * 2008-06-06 2009-12-10 Boston Scientific Scimed, Inc. Medical balloon made with hybrid polymer-ceramic material and method of making and using the same
WO2010015022A1 (en) * 2008-08-05 2010-02-11 The University Of Queensland Antigen-presenting scaffolds

Patent Citations (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459725A (en) * 1964-01-17 1969-08-05 Montedison Spa High molecular weight unsaturated hydrocarbon homopolymers and process for preparing them
US3563973A (en) * 1965-03-04 1971-02-16 Radiation Applic Inc Articles with polymeric memory and method of constructing same
US3383336A (en) * 1966-06-27 1968-05-14 Kuyama Hiroshi Resinous insoluble reaction products
US4080357A (en) * 1976-06-07 1978-03-21 Shell Oil Company Multicomponent halogenated thermoplastic-block copolymer-polymer blends
US4531933A (en) * 1982-12-07 1985-07-30 C. R. Bard, Inc. Helical ureteral stent
US4503569A (en) * 1983-03-03 1985-03-12 Dotter Charles T Transluminally placed expandable graft prosthesis
US5506300A (en) * 1985-01-04 1996-04-09 Thoratec Laboratories Corporation Compositions that soften at predetermined temperatures and the method of making same
US4893623A (en) * 1986-12-09 1990-01-16 Advanced Surgical Intervention, Inc. Method and apparatus for treating hypertrophy of the prostate gland
US5037427A (en) * 1987-03-25 1991-08-06 Terumo Kabushiki Kaisha Method of implanting a stent within a tubular organ of a living body and of removing same
US5089005A (en) * 1987-08-13 1992-02-18 Terumo Kabushiki Kaisha Catheter for the introduction of an expandable member
US4950258A (en) * 1988-01-28 1990-08-21 Japan Medical Supply Co., Ltd. Plastic molded articles with shape memory property
US5496311A (en) * 1988-10-28 1996-03-05 Boston Scientific Corporation Physiologic low stress angioplasty
US5007926A (en) * 1989-02-24 1991-04-16 The Trustees Of The University Of Pennsylvania Expandable transluminally implantable tubular prosthesis
US5100429A (en) * 1989-04-28 1992-03-31 C. R. Bard, Inc. Endovascular stent and delivery system
US4990155A (en) * 1989-05-19 1991-02-05 Wilkoff Howard M Surgical stent method and apparatus
US5282854A (en) * 1989-10-11 1994-02-01 Daikin Industries Ltd. Fluorine-containing block copolymer and artificial lens comprising the same
US5607467A (en) * 1990-09-14 1997-03-04 Froix; Michael Expandable polymeric stent with memory and delivery apparatus and method
US6248129B1 (en) * 1990-09-14 2001-06-19 Quanam Medical Corporation Expandable polymeric stent with memory and delivery apparatus and method
US5187110A (en) * 1990-10-05 1993-02-16 Allied-Signal Inc. Field effect transistor-bipolar transistor darlington pair
USRE38711E1 (en) * 1991-03-08 2005-03-15 Kabushikikaisha Igaki Iryo Sekkei Luminal stent, holding structure therefor and device for attaching luminal stent
US6080177A (en) * 1991-03-08 2000-06-27 Igaki; Keiji Luminal stent, holding structure therefor and device for attaching luminal stent
US6045568A (en) * 1991-03-08 2000-04-04 Igaki; Keiji Luminal stent, holding structure therefor and device for attaching luminal stent
US5278237A (en) * 1991-08-09 1994-01-11 Daicel-Huls Ltd. Sculpturing resin composition and process for sculpturing a sculptured product
US5769883A (en) * 1991-10-04 1998-06-23 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US5421955B1 (en) * 1991-10-28 1998-01-20 Advanced Cardiovascular System Expandable stents and method for making same
US5421955A (en) * 1991-10-28 1995-06-06 Advanced Cardiovascular Systems, Inc. Expandable stents and method for making same
US5755769A (en) * 1992-03-12 1998-05-26 Laboratoire Perouse Implant Expansible endoprosthesis for a human or animal tubular organ, and fitting tool for use thereof
US5645559A (en) * 1992-05-08 1997-07-08 Schneider (Usa) Inc Multiple layer stent
US5762625A (en) * 1992-09-08 1998-06-09 Kabushikikaisha Igaki Iryo Sekkei Luminal stent and device for inserting luminal stent
US5395882A (en) * 1992-09-24 1995-03-07 Rohm Gmbh Chemische Fabrik Light-scattering polystyrene molding compounds, and molded articles produced therefrom
US5900246A (en) * 1993-03-18 1999-05-04 Cedars-Sinai Medical Center Drug incorporating and releasing polymeric coating for bioprosthesis
US5876432A (en) * 1994-04-01 1999-03-02 Gore Enterprise Holdings, Inc. Self-expandable helical intravascular stent and stent-graft
US6517570B1 (en) * 1994-08-31 2003-02-11 Gore Enterprise Holdings, Inc. Exterior supported self-expanding stent-graft
US5741333A (en) * 1995-04-12 1998-04-21 Corvita Corporation Self-expanding stent for a medical device to be introduced into a cavity of a body
US5766188A (en) * 1995-05-08 1998-06-16 Kabushikikaisha Igaki Iryo Sekkei Medical suturing material
US5935506A (en) * 1995-10-24 1999-08-10 Biotronik Meβ- und Therapiegerate GmbH & Co. Ingenieurburo Berlin Method for the manufacture of intraluminal stents of bioresorbable polymeric material
US5880240A (en) * 1996-04-03 1999-03-09 Arakawa Chemical Industries, Ltd. Alkyl-containing porous resin, process for its preparation and its use
US6174305B1 (en) * 1996-04-09 2001-01-16 Endocare, Inc. Urological stent therapy system and method
US5928217A (en) * 1996-04-09 1999-07-27 Endocare, Inc. Urological stent therapy system and method
US6416545B1 (en) * 1996-04-09 2002-07-09 Endocare, Inc. Urological stent therapy system and method
US5889118A (en) * 1996-06-03 1999-03-30 Minnesota Mining And Manufacturing Company Thermomorphic "smart" pressure sensitive adhesives
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5910357A (en) * 1996-07-12 1999-06-08 Nitto Denko Corporation Separation membrane and method of producing the same, and shape memory polymer composition
US5908918A (en) * 1996-07-17 1999-06-01 Chronopol, Inc. Impact modified polylactide
US6596818B1 (en) * 1996-10-08 2003-07-22 Alan M. Zamore Irradiation conversion of thermoplastic to thermoset polymers
US5900444A (en) * 1996-10-08 1999-05-04 Zamore; Alan Irradiation conversion of thermoplastic to thermoset polyurethane
US6086610A (en) * 1996-10-22 2000-07-11 Nitinol Devices & Components Composite self expanding stent device having a restraining element
US6179878B1 (en) * 1996-10-22 2001-01-30 Thomas Duerig Composite self expanding stent device having a restraining element
US5776162A (en) * 1997-01-03 1998-07-07 Nitinol Medical Technologies, Inc. Vessel implantable shape memory appliance with superelastic hinged joint
US6200335B1 (en) * 1997-03-31 2001-03-13 Kabushikikaisha Igaki Iryo Sekkei Stent for vessel
US6413272B1 (en) * 1997-03-31 2002-07-02 Kabushikikaisha Igaki Iryo Sekkei Stent for vessel
US6024764A (en) * 1997-08-19 2000-02-15 Intermedics, Inc. Apparatus for imparting physician-determined shapes to implantable tubular devices
US6395038B1 (en) * 1997-08-19 2002-05-28 Intermedics Inc. Apparatus for imparting physician-determined shapes to implantable tubular devices
US6241691B1 (en) * 1997-12-05 2001-06-05 Micrus Corporation Coated superelastic stent
US6720402B2 (en) * 1998-02-23 2004-04-13 Mnemoscience Gmbh Shape memory polymers
US6388043B1 (en) * 1998-02-23 2002-05-14 Mnemoscience Gmbh Shape memory polymers
US6033413A (en) * 1998-04-20 2000-03-07 Endocare, Inc. Stent delivery system
US6217609B1 (en) * 1998-06-30 2001-04-17 Schneider (Usa) Inc Implantable endoprosthesis with patterned terminated ends and methods for making same
US7331988B2 (en) * 1998-09-08 2008-02-19 Kabushikikaisha Igaki Iryo Sekkei Stent for vessel
US7066952B2 (en) * 1998-09-08 2006-06-27 Kabushikikaisha Igaki Iryo Sekkei Method for manufacturing yarn for vessel stent
US7335226B2 (en) * 1998-09-08 2008-02-26 Kabushikikaisha Igaki Iryo Sekkei Yarn for vessel stent
US6517569B2 (en) * 1998-09-14 2003-02-11 Endocare, Inc. Insertion device for stents and methods for use
US20020055787A1 (en) * 1998-10-15 2002-05-09 Charles D. Lennox Treating urinary retention
US6413273B1 (en) * 1998-11-25 2002-07-02 Israel Aircraft Industries Ltd. Method and system for temporarily supporting a tubular organ
US6390812B1 (en) * 1998-11-30 2002-05-21 Align Technology, Inc. System and method for releasing tooth positioning appliances
US6705861B2 (en) * 1998-11-30 2004-03-16 Align Technology, Inc. System and method for releasing tooth positioning appliances
US6183248B1 (en) * 1998-11-30 2001-02-06 Muhammad Chishti System and method for releasing tooth positioning appliances
US20020015519A1 (en) * 1998-12-11 2002-02-07 Lord Corporation Fiber substrate adhesion and coatings by contact metathesis polymerization
US6958212B1 (en) * 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US6538089B1 (en) * 1999-02-05 2003-03-25 Forskarpatent I Syd Ab Gels with a shape memory
US6368346B1 (en) * 1999-06-03 2002-04-09 American Medical Systems, Inc. Bioresorbable stent
US6364904B1 (en) * 1999-07-02 2002-04-02 Scimed Life Systems, Inc. Helically formed stent/graft assembly
US6858680B2 (en) * 1999-07-20 2005-02-22 Aortech Biomaterials Pty Ltd Shape memory polyurethane or polyurethane-urea polymers
US6086204A (en) * 1999-09-20 2000-07-11 Magnante; Peter C. Methods and devices to design and fabricate surfaces on contact lenses and on corneal tissue that correct the eye's optical aberrations
US7070615B1 (en) * 2000-03-13 2006-07-04 Keiji Igaki Linear material for blood vessel stent and blood vessel stent utilizing same
US20020007222A1 (en) * 2000-04-11 2002-01-17 Ashvin Desai Method and apparatus for supporting a body organ
US6679605B2 (en) * 2000-05-22 2004-01-20 Medennium, Inc. Crystalline polymeric compositions for ophthalmic devices
US20040015261A1 (en) * 2000-08-28 2004-01-22 Hofmann Gregory J. Shape memory polymer or alloy ophthalmic lens mold and methods of forming ophthalmic products
US6348064B1 (en) * 2000-09-01 2002-02-19 Angiolink Corporation Wound site management and wound closure device
US7498042B2 (en) * 2000-11-30 2009-03-03 Kyoto Medical Planning Co., Ltd. Stent for blood vessel and material for stent for blood vessel
US20030033001A1 (en) * 2001-02-27 2003-02-13 Keiji Igaki Stent holding member and stent feeding system
US20030030530A1 (en) * 2001-07-10 2003-02-13 Friwo Geraetebau Gmbh Charging unit for a contactless transfer of electric power as well as a power absorbing device and a charging system
US20030060793A1 (en) * 2001-07-24 2003-03-27 Topolkaraev Vasily A. Disposable products having humidity activated materials with shape-memory
US20030040803A1 (en) * 2001-08-23 2003-02-27 Rioux Robert F. Maintaining an open passageway through a body lumen
US7670302B2 (en) * 2001-12-18 2010-03-02 Boston Scientific Scimed, Inc. Super elastic guidewire with shape retention tip
US7473273B2 (en) * 2002-01-22 2009-01-06 Medtronic Vascular, Inc. Stent assembly with therapeutic agent exterior banding
US6852825B2 (en) * 2002-04-18 2005-02-08 Mnemoscience Gmbh Polyester urethanes
US20040014929A1 (en) * 2002-04-18 2004-01-22 Mnemoscience Gmbh Polyester urethanes
US20040015187A1 (en) * 2002-04-18 2004-01-22 Mnemoscience Corporation Biodegradable shape memory polymeric sutures
US20040024143A1 (en) * 2002-04-18 2004-02-05 Mnemoscience Gmbh Interpenetrating networks
US7008979B2 (en) * 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
US20060041089A1 (en) * 2002-05-02 2006-02-23 Mather Patrick T Castable shape memory polymers
US20040030062A1 (en) * 2002-05-02 2004-02-12 Mather Patrick T. Castable shape memory polymers
US7067606B2 (en) * 2002-07-30 2006-06-27 University Of Connecticut Nonionic telechelic polymers incorporating polyhedral oligosilsesquioxane (POSS) and uses thereof
US20040024098A1 (en) * 2002-07-30 2004-02-05 Mather Patrick T. Nonionic telechelic polymers incorporating polyhedral oligosilsesquioxane (POSS) and uses thereof
US7198639B2 (en) * 2002-09-13 2007-04-03 Bausch & Lomb Incorporated Polysilsesquioxane containing polymeric compositions
US7367990B2 (en) * 2002-09-25 2008-05-06 Kabushikikaisha Igaki Iryo Sekkei Thread for vascular stent and vascular stent using the thread
US20040060428A1 (en) * 2002-10-01 2004-04-01 Sanderson Paul H. Sponson tow plate-mounted helicopter armament apparatus and associated methods
US20040116641A1 (en) * 2002-10-11 2004-06-17 Mather Patrick T. Shape memory polymers based on semicrystalline thermoplastic polyurethanes bearing nanostructured hard segments
US20040122184A1 (en) * 2002-10-11 2004-06-24 Mather Patrick T. Crosslinked polycyclooctene
US20050010275A1 (en) * 2002-10-11 2005-01-13 Sahatjian Ronald A. Implantable medical devices

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Fu et al "Nanoscale development during deformation of polyurethane containing polyhedral oligomeric silsesquioxanes (POSS) molecules" Polymer 42 (2001) 599-611 *
Fu et al "Nanoscale Reinforcement of polyhedral oligomeric silsesquioxane (POSS) in polyurethane elastomer" Polym In 49:437-440 (2000) *
Laine "Organic/Inorganic hybrid materials " 1998 *
RL Hudson "http://www.rlhudson.com/O-Ring%20Book/P041.html" 1/31/2001 (date stamp shown) *
Zhang "effect of methyl methacrylate/polyhedral oligiomeric..." macromolecules 2002 *

Also Published As

Publication number Publication date Type
WO2006115847A3 (en) 2007-10-04 application
EP1874371A2 (en) 2008-01-09 application
EP1874371B1 (en) 2009-05-27 grant
US20160296677A1 (en) 2016-10-13 application
US20050251249A1 (en) 2005-11-10 application
WO2006115847A2 (en) 2006-11-02 application
JP2008536628A (en) 2008-09-11 application
JP5255434B2 (en) 2013-08-07 grant
DE602006006994D1 (en) 2009-07-09 grant
US7976936B2 (en) 2011-07-12 grant

Similar Documents

Publication Publication Date Title
US7824601B1 (en) Process of making a tubular implantable medical device
US7288609B1 (en) Coatings for drug delivery devices based on poly (orthoesters)
US20050271700A1 (en) Poly(ester amide) coating composition for implantable devices
US20040034337A1 (en) Microarray drug delivery coatings
US20080051881A1 (en) Medical devices comprising porous layers for the release of therapeutic agents
US20030153971A1 (en) Metal reinforced biodegradable intraluminal stents
US20070123973A1 (en) Biodegradable device
US20030153972A1 (en) Biodegradable implantable or insertable medical devices with controlled change of physical properties leading to biomechanical compatibility
US20060193892A1 (en) Polymer biodegradable medical device
US20090148591A1 (en) Methods to improve adhesion of polymer coatings over stents
US20080103584A1 (en) Temporal Intraluminal Stent, Methods of Making and Using
US20050163954A1 (en) Medical devices
US20050234538A1 (en) Bioresorbable stent delivery system
US20050245637A1 (en) Methods for modulating thermal and mechanical properties of coatings on implantable devices
US20130129794A1 (en) Poly(Ester Amide)-Based Drug Delivery Systems
US20020082685A1 (en) Apparatus and methods for controlled substance delivery from implanted prostheses
US20080009939A1 (en) Bioabsorbable stent with radiopaque coating
US20070162110A1 (en) Bioabsorbable drug delivery devices
US20060127442A1 (en) Use of supercritical fluids to incorporate biologically active agents into nanoporous medical articles
US7416559B2 (en) Micromantled drug-eluting stent
EP0756853A1 (en) Composite metal and polymer locking stents for drug delivery
US20090076595A1 (en) Medical devices having bioerodable layers for the release of therapeutic agents
US7329413B1 (en) Coatings for drug delivery devices having gradient of hydration and methods for fabricating thereof
US20090182404A1 (en) Biodegradable self-expanding drug-eluting prosthesis
US20080215137A1 (en) Therapeutic driving layer for a medical device

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITY OF CONNECTICUT, CONNECTICUT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MATHER, PATRICK T.;LIU, CHANGDENG;GE, QING;SIGNING DATESFROM 20050601 TO 20050622;REEL/FRAME:025996/0148

Owner name: BOSTON SCIENTIFIC SCIMED, INC., MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SAHATJIAN, RONALD A.;TAN, FRANCISCA;SIGNING DATES FROM 20050615 TO 20050617;REEL/FRAME:025996/0059